Q2KJA5
Gene name |
LAPTM5 |
Protein name |
Lysosomal-associated transmembrane protein 5 |
Names |
Lysosomal-associated multitransmembrane protein 5 |
Species |
Bos taurus (Bovine) |
KEGG Pathway |
bta:512361 |
EC number |
|
Protein Class |
|
Descriptions
The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.
Autoinhibitory domains (AIDs)
Target domain |
|
Relief mechanism |
|
Assay |
cis-regPred |
Accessory elements
No accessory elements
Autoinhibited structure
Activated structure
1 structures for Q2KJA5
| Entry ID | Method | Resolution | Chain | Position | Source |
|---|---|---|---|---|---|
| AF-Q2KJA5-F1 | Predicted | AlphaFoldDB |
42 variants for Q2KJA5
| Variant ID(s) | Position | Change | Description | Diseaes Association | Provenance |
|---|---|---|---|---|---|
| rs478639542 | 4 | R>G | No | EVA | |
| rs447392363 | 4 | R>P | No | EVA | |
| rs433026788 | 5 | A>G | No | EVA | |
| rs433026788 | 5 | A>V | No | EVA | |
| rs450028319 | 6 | A>S | No | EVA | |
| rs435567367 | 9 | R>S | No | EVA | |
| rs455858386 | 11 | T>A | No | EVA | |
| rs472685929 | 12 | C>Y | No | EVA | |
| rs435017080 | 15 | F>I | No | EVA | |
| rs443889110 | 21 | T>S | No | EVA | |
| rs476281507 | 22 | T>A | No | EVA | |
| rs441543587 | 22 | T>I | No | EVA | |
| rs476281507 | 22 | T>P | No | EVA | |
| rs461724563 | 25 | A>G | No | EVA | |
| rs447406332 | 28 | H>P | No | EVA | |
| rs437830431 | 56 | G>A | No | EVA | |
| rs437830431 | 56 | G>D | No | EVA | |
| rs433948890 | 57 | Y>F | No | EVA | |
| rs468630243 | 57 | Y>N | No | EVA | |
| rs433366568 | 60 | I>T | No | EVA | |
| rs464611974 | 60 | I>V | No | EVA | |
| rs448820579 | 62 | E>* | No | EVA | |
| rs465848404 | 64 | V>D | No | EVA | |
| rs523861942 | 78 | L>F | No | EVA | |
| rs526763363 | 78 | L>W | No | EVA | |
| rs519436237 | 79 | S>R | No | EVA | |
| rs457297754 | 134 | S>A | No | EVA | |
| rs474190452 | 139 | M>I | No | EVA | |
| rs438923254 | 158 | M>I | No | EVA | |
| rs459086092 | 164 | L>P | No | EVA | |
| rs482546171 | 166 | F>S | No | EVA | |
| rs449617664 | 171 | H>Q | No | EVA | |
| rs43326426 | 184 | N>T | No | EVA | |
| rs480999132 | 199 | T>P | No | EVA | |
| rs433540661 | 205 | V>I | No | EVA | |
| rs453250522 | 232 | M>I | No | EVA | |
| rs477855970 | 237 | V>A | No | EVA | |
| rs449807229 | 238 | L>R | No | EVA | |
| rs435383339 | 242 | E>* | No | EVA | |
| rs449073675 | 259 | P>H | No | EVA | |
| rs524343384 | 263 | E>G | No | EVA | |
| rs465949403 | 264 | V>G | No | EVA |
No associated diseases with Q2KJA5
No regional properties for Q2KJA5
| Type | Name | Position | InterPro Accession |
|---|---|---|---|
| No domain, repeats, and functional sites for Q2KJA5 | |||
5 GO annotations of cellular component
| Name | Definition |
|---|---|
| integral component of plasma membrane | The component of the plasma membrane consisting of the gene products and protein complexes having at least some part of their peptide sequence embedded in the hydrophobic region of the membrane. |
| lysosomal membrane | The lipid bilayer surrounding the lysosome and separating its contents from the cell cytoplasm. |
| perinuclear region of cytoplasm | Cytoplasm situated near, or occurring around, the nucleus. |
| protein-containing complex | A stable assembly of two or more macromolecules, i.e. proteins, nucleic acids, carbohydrates or lipids, in which at least one component is a protein and the constituent parts function together. |
| transport vesicle | Any of the vesicles of the constitutive secretory pathway, which carry cargo from the endoplasmic reticulum to the Golgi, between Golgi cisternae, from the Golgi to the ER (retrograde transport) or to destinations within or outside the cell. |
2 GO annotations of molecular function
| Name | Definition |
|---|---|
| ubiquitin protein ligase binding | Binding to a ubiquitin protein ligase enzyme, any of the E3 proteins. |
| ubiquitin-dependent protein binding | Binding to a protein upon ubiquitination of the target protein. |
5 GO annotations of biological process
| Name | Definition |
|---|---|
| activation of cysteine-type endopeptidase activity involved in apoptotic process | Any process that initiates the activity of the inactive enzyme cysteine-type endopeptidase in the context of an apoptotic process. |
| defense response to tumor cell | Reactions triggered in response to the presence of a tumor cell that act to protect the cell or organism. |
| induction of programmed cell death | A process which directly activates any of the steps required for programmed cell death. |
| negative regulation of autophagic cell death | Any process that stops, prevents or reduces the frequency, rate or extent of autophagic cell death. |
| positive regulation of lysosomal membrane permeability | Any process that increases the frequency, rate or extent of the passage or uptake of molecules by the lysosomal membrane. |
| 10 | 20 | 30 | 40 | 50 | 60 |
| MAPRAAAIRQ | TCCCFNVRIA | TTALAIYHVI | MSVLLFIEHS | VEVAHGKASC | KFSKTGYLRI |
| 70 | 80 | 90 | 100 | 110 | 120 |
| AELVSSFLLI | TMLFIISLSL | LVGVVKNREK | YLLPFLSLQI | MDFLLCLLTL | MGSYIELPAY |
| 130 | 140 | 150 | 160 | 170 | 180 |
| LKFASRSSRR | VSPSKVPLMT | LQLLDFCLSI | LTLCSSYMEV | PTYLNFKSMN | HMNYLPSQDG |
| 190 | 200 | 210 | 220 | 230 | 240 |
| MTHNQFIKIM | IIFSIAFITV | LILKVYMFKC | VWRCYRLMKC | TNSAEERSGS | KMLQKVVLPS |
| 250 | 260 | ||||
| YEEAVSLPYK | VPEGGPAPPP | YSEV |